
MSD receives MHRA approval for adult-specific pneumococcal vaccine Capvaxive
MSD – known as Merck & Co in the US and Canada – has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for its adult-specific pneumococcal vaccine Capvaxive. The vaccine has been authorised to help protect adults …